Skip to main content
Top
Published in: BMC Urology 1/2023

Open Access 01-12-2023 | Prostate Cancer | Research

Characterization of metabolism-associated molecular patterns in prostate cancer

Authors: Bowei Yang, Yongming Jiang, Jun Yang, Wenbo Zhou, Tongxin Yang, Rongchang Zhang, Jinming Xu, Haixiang Guo

Published in: BMC Urology | Issue 1/2023

Login to get access

Abstract

Background

Metabolism is a hallmark of cancer and it involves in resistance to antitumor treatment. Therefore, the purposes of this study are to classify metabolism-related molecular pattern and to explore the molecular and tumor microenvironment characteristics for prognosis predicting in prostate cancer.

Methods

The mRNA expression profiles and the corresponding clinical information for prostate cancer patients from TCGA, cBioPortal, and GEO databases. Samples were classified using unsupervised non-negative matrix factorization (NMF) clustering based on differentially expressed metabolism-related genes (MAGs). The characteristics of disease-free survival (DFS), clinicopathological characteristics, pathways, TME, immune cell infiltration, response to immunotherapy, and sensitivity to chemotherapy between subclusters were explored. A prognostic signature was constructed by LASSO cox regression analysis based on differentially expressed MAGs and followed by the development for prognostic prediction.

Results

A total of 76 MAGs between prostate cancer samples and non-tumorous samples were found, then 489 patients were divided into two metabolism-related subclusters for prostate cancer. The significant differences in clinical characteristics (age, T/N stage, Gleason) and DFS between two subclusters. Cluster 1 was associated with cell cycle and metabolism-related pathways, and epithelial-mesenchymal transition (EMT), etc., involved in cluster 2. Moreover, lower ESTIMATE/immune/stromal scores, lower expression of HLAs and immune checkpoint-related genes, and lower half-maximal inhibitory concentration (IC50) values in cluster 1 compared with cluster 2. The 10 MAG signature was identified and constructed a risk model for DFS predicting. The patients with high-risk scores showed poorer DFS. The area under the curve (AUC) values for 1-, 3-, 5-year DFS were 0.744, 0.731, 0.735 in TCGA-PRAD dataset, and 0.668, 0.712, 0.809 in GSE70768 dataset, 0.763, 0.802, 0.772 in GSE70769 dataset. Besides, risk score and Gleason score were identified as independent factors for DFS predicting, and the AUC values of risk score and Gleason score were respectively 0.743 and 0.738. The nomogram showed a favorable performance in DFS predicting.

Conclusion

Our data identified two metabolism-related molecular subclusters for prostate cancer that were distinctly characterized in prostate cancer. Metabolism-related risk profiles were also constructed for prognostic prediction.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
go back to reference Daniyal M, et al. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev. 2014;15(22):9575–8.PubMedCrossRef Daniyal M, et al. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev. 2014;15(22):9575–8.PubMedCrossRef
3.
go back to reference Rebbeck TR, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer. 2013;2013:560857.PubMedPubMedCentralCrossRef Rebbeck TR, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer. 2013;2013:560857.PubMedPubMedCentralCrossRef
4.
go back to reference Clinton SK, Giovannucci EL, Hursting SD. The world cancer research fund/American institute for cancer research third expert report on diet, nutrition, physical activity, and cancer: impact and future directions. J Nutr. 2020;150(4):663–71.PubMedCrossRef Clinton SK, Giovannucci EL, Hursting SD. The world cancer research fund/American institute for cancer research third expert report on diet, nutrition, physical activity, and cancer: impact and future directions. J Nutr. 2020;150(4):663–71.PubMedCrossRef
5.
go back to reference Pernar CH, et al. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med, 2018. 8(12). Pernar CH, et al. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med, 2018. 8(12).
6.
go back to reference Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532–42.PubMedCrossRef Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532–42.PubMedCrossRef
7.
go back to reference Epstein JI, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2016;40(2):244–52.PubMedCrossRef Epstein JI, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2016;40(2):244–52.PubMedCrossRef
8.
go back to reference Epstein JI, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. 2016; 69(3): 428–35. Epstein JI, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. 2016; 69(3): 428–35.
9.
go back to reference Weinreb JC, et al. PI-RADS prostate imaging—reporting and data system: 2015, version 2. Eur Urol. 2016;69(1):16–40.PubMedCrossRef Weinreb JC, et al. PI-RADS prostate imaging—reporting and data system: 2015, version 2. Eur Urol. 2016;69(1):16–40.PubMedCrossRef
10.
go back to reference Sommariva S, et al. Prognostic value of the cell cycle progression score in patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69(1):107–15.PubMedCrossRef Sommariva S, et al. Prognostic value of the cell cycle progression score in patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69(1):107–15.PubMedCrossRef
11.
go back to reference Sardana G, Diamandis EP. Biomarkers for the diagnosis of new and recurrent prostate cancer. Biomark Med. 2012;6(5):587–96.PubMedCrossRef Sardana G, Diamandis EP. Biomarkers for the diagnosis of new and recurrent prostate cancer. Biomark Med. 2012;6(5):587–96.PubMedCrossRef
12.
go back to reference Jalloh M, Cooperberg MR. Implementation of PSA-based active surveillance in prostate cancer. Biomark Med. 2014;8(5):747–53.PubMedCrossRef Jalloh M, Cooperberg MR. Implementation of PSA-based active surveillance in prostate cancer. Biomark Med. 2014;8(5):747–53.PubMedCrossRef
13.
go back to reference Filson CP, Marks LS, Litwin MS. Expectant management for men with early stage prostate cancer. CA: Cancer J Clin 2015. 65(4): 264–82. Filson CP, Marks LS, Litwin MS. Expectant management for men with early stage prostate cancer. CA: Cancer J Clin 2015. 65(4): 264–82.
15.
go back to reference Yu JB, et al. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol. 2014;32(12):1195–201.PubMedPubMedCentralCrossRef Yu JB, et al. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol. 2014;32(12):1195–201.PubMedPubMedCentralCrossRef
17.
go back to reference Nead KT, et al. Association between androgen deprivation therapy and risk of dementia. JAMA Oncol. 2017;3(1):49–55.PubMedCrossRef Nead KT, et al. Association between androgen deprivation therapy and risk of dementia. JAMA Oncol. 2017;3(1):49–55.PubMedCrossRef
18.
go back to reference Parker C, Sartor O. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;365(8):767.PubMed Parker C, Sartor O. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;365(8):767.PubMed
19.
go back to reference Schellhammer PF, et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology. 2013;81(6):1297–302.PubMedCrossRef Schellhammer PF, et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology. 2013;81(6):1297–302.PubMedCrossRef
20.
21.
go back to reference Beier AK, et al. Metabolic changes during prostate cancer development and progression. J Cancer Res Clin Oncol. 2023;149(5):2259–70.PubMedCrossRef Beier AK, et al. Metabolic changes during prostate cancer development and progression. J Cancer Res Clin Oncol. 2023;149(5):2259–70.PubMedCrossRef
22.
go back to reference Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–80.PubMedCrossRef Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–80.PubMedCrossRef
24.
go back to reference Li Z, Zhang H. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci. 2016;73(2):377–92.PubMedCrossRef Li Z, Zhang H. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci. 2016;73(2):377–92.PubMedCrossRef
26.
go back to reference Bader DA, McGuire SE. Tumour metabolism and its unique properties in prostate adenocarcinoma. Nat Rev Urol. 2020;17(4):214–31.PubMedCrossRef Bader DA, McGuire SE. Tumour metabolism and its unique properties in prostate adenocarcinoma. Nat Rev Urol. 2020;17(4):214–31.PubMedCrossRef
27.
go back to reference Peitzsch C, et al. Metabolic regulation of prostate cancer heterogeneity and plasticity. Semin Cancer Biol. 2020. Peitzsch C, et al. Metabolic regulation of prostate cancer heterogeneity and plasticity. Semin Cancer Biol. 2020.
28.
go back to reference Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol. 2011;223(2):283–94.PubMedCrossRef Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol. 2011;223(2):283–94.PubMedCrossRef
30.
go back to reference Strmiska V, et al. Prostate cancer-specific hallmarks of amino acids metabolism: towards a paradigm of precision medicine. Biochim Biophys Acta Rev Cancer. 2019;1871(2):248–58.PubMedCrossRef Strmiska V, et al. Prostate cancer-specific hallmarks of amino acids metabolism: towards a paradigm of precision medicine. Biochim Biophys Acta Rev Cancer. 2019;1871(2):248–58.PubMedCrossRef
31.
go back to reference Giskeødegård GF, Bertilsson H, Selnæs KM. Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. PLoS One, 2013;8(4): e62375. Giskeødegård GF, Bertilsson H, Selnæs KM. Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. PLoS One, 2013;8(4): e62375.
32.
go back to reference Bindea G, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–95.PubMedCrossRef Bindea G, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–95.PubMedCrossRef
33.
go back to reference Kanehisa M, et al. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587-d592.PubMedCrossRef Kanehisa M, et al. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587-d592.PubMedCrossRef
36.
39.
go back to reference Cruz-Bermúdez A, et al. Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition. Free Radic Biol Med. 2019;135:167–81.PubMedCrossRef Cruz-Bermúdez A, et al. Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition. Free Radic Biol Med. 2019;135:167–81.PubMedCrossRef
42.
go back to reference Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43(3):435–49.PubMedCrossRef Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43(3):435–49.PubMedCrossRef
43.
go back to reference Alberto M., et al. Dysfunctional lipid metabolism-the basis for how genetic abnormalities express the phenotype of aggressive prostate cancer. Cancers (Basel), 2023. 15(2). Alberto M., et al. Dysfunctional lipid metabolism-the basis for how genetic abnormalities express the phenotype of aggressive prostate cancer. Cancers (Basel), 2023. 15(2).
44.
go back to reference Berchuck JE, et al. The prostate cancer androgen receptor cistrome in African American Men associates with upregulation of lipid metabolism and immune response. Cancer Res. 2022;82(16):2848–59.PubMedPubMedCentralCrossRef Berchuck JE, et al. The prostate cancer androgen receptor cistrome in African American Men associates with upregulation of lipid metabolism and immune response. Cancer Res. 2022;82(16):2848–59.PubMedPubMedCentralCrossRef
45.
go back to reference Vellaichamy A, et al. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. PLoS ONE. 2009;4(9):e7075.PubMedPubMedCentralCrossRef Vellaichamy A, et al. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. PLoS ONE. 2009;4(9):e7075.PubMedPubMedCentralCrossRef
46.
go back to reference Vasquez JL, et al. Inhibition of base excision repair by natamycin suppresses prostate cancer cell proliferation. Biochimie. 2020;168:241–50.PubMedCrossRef Vasquez JL, et al. Inhibition of base excision repair by natamycin suppresses prostate cancer cell proliferation. Biochimie. 2020;168:241–50.PubMedCrossRef
47.
go back to reference Chen, J., et al. CMBD: a manually curated cancer metabolic biomarker knowledge database. Database (Oxford), 2021;2021. Chen, J., et al. CMBD: a manually curated cancer metabolic biomarker knowledge database. Database (Oxford), 2021;2021.
48.
go back to reference Sztupinszki Z, et al. Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations. Clin Cancer Res. 2020;26(11):2673–80.PubMedPubMedCentralCrossRef Sztupinszki Z, et al. Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations. Clin Cancer Res. 2020;26(11):2673–80.PubMedPubMedCentralCrossRef
49.
go back to reference Jarzen J, Diamanduros A, Scarpinato KD. Mismatch repair proteins in recurrent prostate cancer. Adv Clin Chem. 2013;60:65–84.PubMedCrossRef Jarzen J, Diamanduros A, Scarpinato KD. Mismatch repair proteins in recurrent prostate cancer. Adv Clin Chem. 2013;60:65–84.PubMedCrossRef
51.
go back to reference Gong XJ, et al. Knowledge enrichment analysis for human tissue-specific genes uncover new biological insights. J Integr Bioinform. 2012;9(2):194.PubMed Gong XJ, et al. Knowledge enrichment analysis for human tissue-specific genes uncover new biological insights. J Integr Bioinform. 2012;9(2):194.PubMed
52.
go back to reference Cui, X.F., et al. Identification of competing endogenous RNA network in laryngeal squamous cell carcinoma. Oral Dis. 2021. Cui, X.F., et al. Identification of competing endogenous RNA network in laryngeal squamous cell carcinoma. Oral Dis. 2021.
53.
go back to reference Wang JL, Wang Y, Ren GP. Identification of PTPRR and JAG1 as key genes in castration-resistant prostate cancer by integrated bioinformatics methods(). J Zhejiang Univ Sci B. 2020;21(3):246–55.PubMedPubMedCentralCrossRef Wang JL, Wang Y, Ren GP. Identification of PTPRR and JAG1 as key genes in castration-resistant prostate cancer by integrated bioinformatics methods(). J Zhejiang Univ Sci B. 2020;21(3):246–55.PubMedPubMedCentralCrossRef
54.
go back to reference Ardura, J.A., et al., Role of calcium signaling in prostate cancer progression: effects on cancer hallmarks and bone metastatic mechanisms. Cancers (Basel), 2020. 12(5). Ardura, J.A., et al., Role of calcium signaling in prostate cancer progression: effects on cancer hallmarks and bone metastatic mechanisms. Cancers (Basel), 2020. 12(5).
55.
56.
go back to reference Kent LN, Leone G. The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 2019;19(6):326–38.PubMedCrossRef Kent LN, Leone G. The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 2019;19(6):326–38.PubMedCrossRef
57.
go back to reference Li P, et al. E2F transcription factor 2-activated DLEU2 contributes to prostate tumorigenesis by upregulating serum and glucocorticoid-induced protein kinase 1. Cell Death Dis. 2022;13(1):77.PubMedPubMedCentralCrossRef Li P, et al. E2F transcription factor 2-activated DLEU2 contributes to prostate tumorigenesis by upregulating serum and glucocorticoid-induced protein kinase 1. Cell Death Dis. 2022;13(1):77.PubMedPubMedCentralCrossRef
58.
go back to reference Wang D, et al. Comprehensive analysis of the functional and prognostic value of E2F transcription factors in human prostate cancer through data mining and experimental validation. Transl Cancer Res. 2021;10(12):5095–109.PubMedPubMedCentralCrossRef Wang D, et al. Comprehensive analysis of the functional and prognostic value of E2F transcription factors in human prostate cancer through data mining and experimental validation. Transl Cancer Res. 2021;10(12):5095–109.PubMedPubMedCentralCrossRef
59.
go back to reference Ding Q, et al. Dioscin inhibits the growth of human osteosarcoma by inducing G2/M-phase arrest, apoptosis, and GSDME-dependent cell death in vitro and in vivo. J Cell Physiol. 2020;235(3):2911–24.PubMedCrossRef Ding Q, et al. Dioscin inhibits the growth of human osteosarcoma by inducing G2/M-phase arrest, apoptosis, and GSDME-dependent cell death in vitro and in vivo. J Cell Physiol. 2020;235(3):2911–24.PubMedCrossRef
60.
go back to reference Zhang Y, Liu JL, Wang J. KRAS gene silencing inhibits the activation of PI3K-Akt-mTOR signaling pathway to regulate breast cancer cell epithelial-mesenchymal transition, proliferation and apoptosis. Eur Rev Med Pharmacol Sci. 2020;24(6):3085–96.PubMed Zhang Y, Liu JL, Wang J. KRAS gene silencing inhibits the activation of PI3K-Akt-mTOR signaling pathway to regulate breast cancer cell epithelial-mesenchymal transition, proliferation and apoptosis. Eur Rev Med Pharmacol Sci. 2020;24(6):3085–96.PubMed
61.
go back to reference Li H, et al. A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer. Front Immunol. 2022;13:982628.PubMedPubMedCentralCrossRef Li H, et al. A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer. Front Immunol. 2022;13:982628.PubMedPubMedCentralCrossRef
62.
go back to reference Sharma M, Miyamoto H. Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer. Transl Androl Urol. 2018;7(Suppl 4):S484-s489.PubMedPubMedCentralCrossRef Sharma M, Miyamoto H. Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer. Transl Androl Urol. 2018;7(Suppl 4):S484-s489.PubMedPubMedCentralCrossRef
63.
go back to reference Bell PD, et al. Limited adenocarcinoma of the prostate on needle core biopsy. Arch Pathol Lab Med. 2022;146(4):469–77.PubMedCrossRef Bell PD, et al. Limited adenocarcinoma of the prostate on needle core biopsy. Arch Pathol Lab Med. 2022;146(4):469–77.PubMedCrossRef
Metadata
Title
Characterization of metabolism-associated molecular patterns in prostate cancer
Authors
Bowei Yang
Yongming Jiang
Jun Yang
Wenbo Zhou
Tongxin Yang
Rongchang Zhang
Jinming Xu
Haixiang Guo
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2023
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-023-01275-w

Other articles of this Issue 1/2023

BMC Urology 1/2023 Go to the issue